Cold Pain Therapy Market Research, In-Depth Analysis, Key Players, Applications, Forecast 2023

According to the new market research report "Cold Pain Therapy Market by Product (OTC (Gels, Sprays, Patches, Cold Packs, Wraps, Pads, and Roll-Ons), Prescription-Based (Motorized, Non-Motorized Devices), Applications (Musculoskeletal Disorders, Post-Operative Therapy, Sports Medicine, and Post-Trauma Therapy) - Global Forecast to 2023", published by MarketsandMarkets™, the Global Cold Pain Therapy Market is projected to reach USD 2.12 Billion by 2023 from USD 1.69 Billion in 2018, at a CAGR of 4.6% during the forecast period.

Factors such as the increasing incidence of sports injuries and a rising emphasis on exercise, the growing number of hip and knee surgeries across the globe, and a rising need for safer pain management modalities (as compared to oral therapy) are expected to drive the demand for cold pain therapy during the study period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55543905

The OTC products segment is expected to register the highest growth rate during the forecast period

Based on product, the Cold Pain Therapy Market is divided into OTC products and prescription products. OTC products are expected to grow at the highest CAGR during the forecast period. The high patient preference for topical pharmaceuticals as compared to oral medications, owing to their lower side effects, fast pain relief, and convenience, is expected to drive the growth of the OTC products segment in the next five years.

Browse and in-depth TOC on "Cold Pain Therapy Market"

106 - Tables

126 - Figures

273 - Pages

Musculoskeletal disorders are estimated to form the largest segment of the market, by application

The Cold Pain Therapy Market is segmented, by application, into musculoskeletal disorders, post-operative therapy, sports medicine, and post-trauma therapy. The musculoskeletal disorders segment is expected to account for the largest share of the Cold Pain Therapy Market in 2018, owing to the increasing incidence of arthritis, osteoarthritis, back pain, and joint pain; increasing trend of self-care; and the growing preference for topical analgesics to manage musculoskeletal pain.

In 2017, North America accounted for the largest share of the Cold Pain Therapy Market

Geographically, the Cold Pain Therapy Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2017. The growing geriatric population, the high incidence of arthritis and sports injuries, product launches, the large number of surgeries, and stringent regulations on opioid prescription are expected to drive the growth of cold pain therapy products this region.

Read a Press-Release on “Cold Pain Therapy Market”:

https://www.marketsandmarkets.com/PressReleases/cold-pain-therapy.asp

As of 2017, the major players in the Cold Pain Therapy Market are Sanofi (France), DJO Finance (US), and Pfizer (US). Other players in this market include 3M (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson (US), Medline Industries (US), Össur (Iceland), Performance Health (US), Beiersdorf (Germany) Rohto Pharmaceutical (US), Breg (US), Romsons Group of Industries (India), Custom Ice (US), and Unexo Life Sciences (India).

Humanized Mouse and Rat Model Market Growth and Analysis, Industry Trends, Size, Shares, Forecast to 2022

According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets™, The humanized rat models market is expected to reach USD 8.9 Million, at a CAGR of 8.4% during the forecast period. The humanized mouse models market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period.

Growth in this market can primarily be attributed to factors such as the growing demand of personalized medicine, continuous support in the form of investments and grants from the government and private sectors, increasing number of R&D activities in pharmaceutical and biotechnology companies, and the increasing number of research activities involving humanized models. Increasing production of monoclonal antibodies and rising demand for humanized rat models are expected to provide a wide range of growth opportunities for players in the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

The oncology segment commanded the largest share of the humanized mouse models market.

By application, the humanized mouse models market is categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the humanized mouse models market in 2017. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.

Browse and in-depth TOC on "Humanized Mouse and Rat Model Market"

94 - Tables

42 - Figures

189 - Pages

Cell-based humanized mouse models to grow at the highest CAGR during the forecast period

By type, the humanized mouse models market is categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based humanized mouse models market and is expected to grow at the highest CAGR during the forecast period.

Contract Research Organizations (CROs) to dominate the humanized mouse models market during the forecast period

By end user, the humanized mouse models market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CRO), and academic & research institutions. The contract research organizations (CROs) segment is projected to grow at the highest CAGR during the forecast period. Growth in this segment is largely due to the increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs).

North America dominated the market in 2017

North America dominated the global humanized mouse models market in 2017. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

Read More About Humanized Mouse and Rat Model Market: https://www.marketsandmarkets.com/PressReleases/humanized-mouse-model.asp

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).